Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.[ Read More ]
The intrinsic value of one VTRS stock under the base case scenario is HIDDEN Compared to the current market price of 12.8 USD, Viatris Inc. is HIDDEN
Current Assets | 13 B |
Cash & Short-Term Investments | 1.18 B |
Receivables | 4.04 B |
Other Current Assets | 7.75 B |
Non-Current Assets | 34.7 B |
Long-Term Investments | 1.14 B |
PP&E | 3.01 B |
Other Non-Current Assets | 30.6 B |
Current Liabilities | 7.78 B |
Accounts Payable | 1.38 B |
Short-Term Debt | 2.02 B |
Other Current Liabilities | 4.38 B |
Non-Current Liabilities | 19.4 B |
Long-Term Debt | 16.4 B |
Other Non-Current Liabilities | 3.09 B |
Revenue | 15.4 B |
Cost Of Revenue | 8.99 B |
Gross Profit | 6.44 B |
Operating Expenses | 5.97 B |
Operating Income | 766 M |
Other Expenses | 712 M |
Net Income | 54.7 M |
Net Income | 54.7 M |
Depreciation & Amortization | 2.74 B |
Capital Expenditures | -474 M |
Stock-Based Compensation | 181 M |
Change in Working Capital | -711 M |
Others | 431 M |
Free Cash Flow | 2.33 B |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
6 days ago
Nov 11, 2024
|
Sell 347 K USD
|
Campbell Paul
See Remarks |
- 26925
|
12.876 USD |
1 year ago
Oct 26, 2023
|
Bought 171 USD
|
KORMAN HARRY
Director |
+ 19
|
9.007 USD |
2 years ago
Mar 16, 2022
|
Bought 2.49 K USD
|
KORMAN HARRY
Director |
+ 238.76
|
10.421 USD |
2 years ago
Mar 04, 2022
|
Bought 11.6 K USD
|
KORMAN HARRY
Director |
+ 1150
|
10.079 USD |
2 years ago
Dec 16, 2021
|
Bought 2.26 K USD
|
KORMAN HARRY
Director |
+ 176.17
|
12.836 USD |
3 years ago
Sep 16, 2021
|
Bought 2.24 K USD
|
KORMAN HARRY
Director |
+ 162.44
|
13.811 USD |
3 years ago
Jun 16, 2021
|
Bought 2.23 K USD
|
KORMAN HARRY
Director |
+ 144.73
|
15.391 USD |
3 years ago
Mar 09, 2021
|
Bought 4.86 K USD
|
KORMAN HARRY
Director |
+ 349
|
13.939 USD |
3 years ago
Feb 25, 2021
|
Bought 10.7 K USD
|
KORMAN HARRY
Director |
+ 713
|
14.966 USD |
3 years ago
Jan 15, 2021
|
Bought 14.2 K USD
|
KORMAN HARRY
Director |
+ 837
|
16.993 USD |
3 years ago
Dec 11, 2020
|
Bought 10.5 K USD
|
KORMAN HARRY
Director |
+ 613
|
17.147 USD |
2 months ago
Sep 12, 2024
|
Sell 1.63 M USD
|
Malik Rajiv
Director |
- 139681
|
11.6563 USD |
2 months ago
Sep 12, 2024
|
Sell 707 K USD
|
Malik Rajiv
Director |
- 60319
|
11.7136 USD |
2 months ago
Aug 28, 2024
|
Sell 595 K USD
|
Malik Rajiv
Director |
- 50000
|
11.9015 USD |
2 months ago
Aug 30, 2024
|
Sell 600 K USD
|
Malik Rajiv
Director |
- 50000
|
12 USD |
2 months ago
Aug 21, 2024
|
Sell 1.18 M USD
|
Malik Rajiv
Director |
- 100000
|
11.7526 USD |
2 months ago
Aug 22, 2024
|
Sell 1.17 M USD
|
Malik Rajiv
Director |
- 100000
|
11.7263 USD |
2 months ago
Aug 23, 2024
|
Sell 1.18 M USD
|
Malik Rajiv
Director |
- 100000
|
11.751 USD |
5 months ago
Jun 13, 2024
|
Sell 901 K USD
|
Malik Rajiv
Director |
- 85660
|
10.5153 USD |
5 months ago
Jun 14, 2024
|
Sell 2.69 M USD
|
Malik Rajiv
Director |
- 264300
|
10.1789 USD |
5 months ago
May 28, 2024
|
Sell 928 K USD
|
Roman Brian
Chief Legal Officer |
- 89419
|
10.3829 USD |
8 months ago
Mar 13, 2024
|
Sell 3.02 M USD
|
Mauro Anthony
See Remarks |
- 250000
|
12.0948 USD |
8 months ago
Mar 05, 2024
|
Sell 300 K USD
|
Campbell Paul
See Remarks |
- 24353
|
12.33 USD |
8 months ago
Mar 05, 2024
|
Sell 247 K USD
|
Lyons Dillon JoEllen
Director |
- 20000
|
12.36 USD |
8 months ago
Mar 04, 2024
|
Sell 223 K USD
|
Ni Xiangyang (Sean)
President, Greater China |
- 17755
|
12.5394 USD |
8 months ago
Mar 04, 2024
|
Sell 46.7 K USD
|
Ni Xiangyang (Sean)
President, Greater China |
- 3777
|
12.3582 USD |
8 months ago
Feb 23, 2024
|
Sell 54 K USD
|
Cuneo Andrew
See Remarks |
- 4000
|
13.5 USD |
9 months ago
Feb 15, 2024
|
Sell 50 K USD
|
Cuneo Andrew
See Remarks |
- 4000
|
12.5 USD |
10 months ago
Jan 04, 2024
|
Sell 46 K USD
|
Cuneo Andrew
See Remarks |
- 4000
|
11.5 USD |
11 months ago
Dec 14, 2023
|
Sell 42 K USD
|
Cuneo Andrew
See Remarks |
- 4000
|
10.5 USD |
11 months ago
Nov 24, 2023
|
Sell 140 K USD
|
Ni Xiangyang (Sean)
President, Greater China |
- 14937
|
9.3688 USD |
1 year ago
Mar 06, 2023
|
Sell 34.9 K USD
|
Ni Xiangyang (Sean)
President, Greater China |
- 3148
|
11.0835 USD |
1 year ago
Mar 03, 2023
|
Sell 34.6 K USD
|
Ni Xiangyang (Sean)
President, Greater China |
- 3093
|
11.1798 USD |
1 year ago
Feb 28, 2023
|
Sell 58.9 K USD
|
Ni Xiangyang (Sean)
President, Greater China |
- 5250
|
11.2178 USD |
1 year ago
Nov 25, 2022
|
Sell 140 K USD
|
Ni Xiangyang (Sean)
President, Greater China |
- 12800
|
10.9547 USD |
2 years ago
Aug 17, 2022
|
Sell 99.9 K USD
|
van der Meer Mohr Pauline
director: |
- 9440
|
10.5839 USD |
2 years ago
May 27, 2022
|
Sell 106 K USD
|
Taddese Menassie
See Remarks |
- 8813
|
12.0737 USD |
2 years ago
Mar 15, 2022
|
Bought 26.7 K USD
|
CORNWELL W DON
director: |
+ 2700
|
9.8968 USD |
2 years ago
Mar 15, 2022
|
Bought 497 K USD
|
GOETTLER MICHAEL
Chief Executive Officer |
+ 50352
|
9.866 USD |
2 years ago
Mar 09, 2022
|
Sell 2.52 M USD
|
COURY ROBERT J
Executive Chairman |
- 250000
|
10.0731 USD |